Which indications should we prioritise for follow-on Phase 3 clinical programs?

Eradigm was tasked with evaluating the opportunity for a new drug across five potential orphan indications, which spanned from rare nephrology to dermatology conditions.

We quantified the opportunity scientifically, clinically and commercially across all indications to provide a clear business case for prioritisation. This enabled our client to establish strategic launch sequence to maximise the lifetime revenues of their drug.